Patients with baseline comorbidities implying immunocompromise are at a high risk for invasive fungal infection acquisition, such as patients with haematological malignancies, solid tumours, or solid organ transplantations. Additionally, traumas or near-drowning events can also be the trigger for a later fungal infection in otherwise healthy patients.
It is of utmost relevance to diagnose and treat such patients as soon as possible, in order to avoid late diagnoses, secondary comorbidities or even mortality. Aspergillus spp. and Candida spp., together with endemic fungi are the most common infections due to these pathogens. However, there is still lack of knowledge regarding diagnostic and clinical management in other fungi with less incidence Additionally, new antifungal options are on the pipeline (i.e., fosmanogepix, ibrexfungerp, olorofim, rezafungin), which can improve the management of these patients.
The goal of this Research Topic is to:
- Provide light regarding the best diagnostic approach for patients
with invasive fungal infections.
- Summarize experiences in the management of patients with invasive
fungal infections at mono- or multicentric studies.
- Describe novel laboratory-based results from antifungals in the
pipeline (fosmanogepix, ibrexfungerp, olorofim, rezafungin…)
- Characterise patients with novel features of invasive fungal
infections.
- Depict fungal infections associated to other pathogens (i.e., bacteria
and viruses).
- Decipher new laboratory-based diagnostic procedures.
- Interpret pathologic features observed in imaging procedures
associated to invasive fungal infections.
Patients with baseline comorbidities implying immunocompromise are at a high risk for invasive fungal infection acquisition, such as patients with haematological malignancies, solid tumours, or solid organ transplantations. Additionally, traumas or near-drowning events can also be the trigger for a later fungal infection in otherwise healthy patients.
It is of utmost relevance to diagnose and treat such patients as soon as possible, in order to avoid late diagnoses, secondary comorbidities or even mortality. Aspergillus spp. and Candida spp., together with endemic fungi are the most common infections due to these pathogens. However, there is still lack of knowledge regarding diagnostic and clinical management in other fungi with less incidence Additionally, new antifungal options are on the pipeline (i.e., fosmanogepix, ibrexfungerp, olorofim, rezafungin), which can improve the management of these patients.
The goal of this Research Topic is to:
- Provide light regarding the best diagnostic approach for patients
with invasive fungal infections.
- Summarize experiences in the management of patients with invasive
fungal infections at mono- or multicentric studies.
- Describe novel laboratory-based results from antifungals in the
pipeline (fosmanogepix, ibrexfungerp, olorofim, rezafungin…)
- Characterise patients with novel features of invasive fungal
infections.
- Depict fungal infections associated to other pathogens (i.e., bacteria
and viruses).
- Decipher new laboratory-based diagnostic procedures.
- Interpret pathologic features observed in imaging procedures
associated to invasive fungal infections.
